.Pharmacolibrary.Drugs.ATC.J.J01DC07

Information

Cefotiam is a second-generation cephalosporin antibiotic used to treat a variety of bacterial infections. It is primarily active against both gram-positive and gram-negative bacteria. Cefotiam is approved in several countries, particularly in Asia and parts of Europe, but is not approved by the FDA in the United States.

Pharmacokinetics

Reported pharmacokinetic parameters in healthy adult volunteers, single intravenous bolus administration.

References

1. Segal, JL, & Brunnemann, SR (1989). Clinical pharmacokinetics in patients with spinal cord injuries. Clinical pharmacokinetics 17(2) 109–129. DOI:10.2165/00003088-198917020-00004 PUBMED:https://pubmed.ncbi.nlm.nih.gov/2673605

2. Shah, NR, et al., & Sörgel, F (2019). Novel Population Pharmacokinetic Approach to Explain the Differences between Cystic Fibrosis Patients and Healthy Volunteers via Protein Binding. Pharmaceutics 11(6) –. DOI:10.3390/pharmaceutics11060286 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31216743

Revisions

• 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)